Neeva Brings Responsible, Citation-Backed AI Powered Search to Europe
Advert and tracker-free search engine Neeva has today launched NeevaAI in Europe, which harnesses the power of artificial intelligence (AI) to deliver an experience that combines the best of large language models such as ChatGPT with the authority and timeliness of search.
Following a successful beta launch in the US in December 2022, NeevaAI is available to Free Basic and Premium users across the world from today. NeevaAI will be launching its English Language version in the UK and Canada, as well as local language versions in Germany, France and Spain.
NeevaAI provides a synthesised single answer with linked sources pulled together from the most relevant sites for a query, allowing users to determine the authenticity and reliability of the cited sources. The feature offers current information by crawling hundreds of millions of pages a day and serving from its independent index of billions of pages. By combining AI with Neeva's in-house search stack that eschews ads and advertisers, results are fast, timely, bias-free and relevant.
Real-time summaries backed by sources
Unlike other AI search offerings, NeevaAI offers current information to the user by interrogating a page, understanding its contents and incoming links to determine whether the page is useful and authoritative and cite the information source. NeevaAI does this in real time as the web changes, which is vital in our fast paced world.
In a feature unique to Neeva, NeevaAI also provides citation cards, in which a search query returns a visual search result with machine learning summaries from all the top results and swipeable cards highlighting authoritative information about the researched topic. The cards also suggest important research questions for the searcher.
Neeva Founder and CEO, Sridhar Ramaswamy comments: “AI is already beginning to make search one of the first and most clearly disrupted industries. NeevaAI leverages in-house LLMs and refined training models with its full system search stack to bring authentic real time AI search to the everyones. Our goal has been to responsibly integrate AI and provide authoritative answers that you can trust.”
Support for publishers in a post-ChatGPT world
Publishers and content creators stand to be greatly impacted by certain AI search models. AI will fundamentally shift individuals’ relationship to finding and consuming information. For publishers, this should be canary in the coal mine, and failing to adapt to this new reality could prove catastrophic for their businesses.
Nowhere is the threat more immediate than in search. As search engines become answer engines, publisher content will get sucked into the AI bots and served back to users without attribution or links. Without links embedded in the AI answer, users won’t find their way to a publisher’s website, effectively choking off the referral traffic pipeline. Significant drops in referral traffic will lead to material impacts on ad revenue especially at a time when most publishers are fighting just to stay afloat. To make matters worse, that same content will also be used to further train large language models (LLMs) exacerbating the publisher’s dilemma.
Neeva is committed to helping publishers leverage AI and LLMs to re-take ownership of the relationships with their users. Neeva is working to help publishers integrate fluent AI search natively in their websites allowing users to discover and consume content seamlessly. Moreover, to support publishers, whose referral traffic is now at greater risk from AI answer bots, Neeva has committed 20% of its topline revenue to content creator and publisher partners when their content is used to directly answer a Neeva customer’s query.
Since launching in the US in 2021, and Europe in late 2022, Neeva has amassed nearly 2 million users. It has built one of the largest independent search stacks crawling hundreds of millions of pages a day and an index of billions. By combining AI with Neeva’s in-house search stack, NeevaAI’s results are lightning fast, timely, and relevant.
ENDS
About Neeva
Neeva is the world’s first ads-free, private subscription search engine powered by AI. Neeva focuses entirely on the consumer, delivering only real, high quality, trustworthy results. Neeva is leading a new AI frontier by leveraging in-house LLMs and refined training models with our full system search stack to bring authentic real-time AI search to everyone. Neeva blocks third-party website trackers, and will never sell or share customer data with anyone, especially advertisers. Neeva also makes it easy to search within personal email accounts, calendars, and cloud storage platforms surfacing the most important information from the same familiar search box. The company was founded by former executives from Google and YouTube. Learn more and start searching today at neeva.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230213005065/en/
Contact information
Contact details
press@neeva.co
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
